These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 34349535)

  • 1. MAFLD Criteria May Overlook a Subtype of Patient with Steatohepatitis and Significant Fibrosis.
    Huang J; Xue W; Wang M; Wu Y; Singh M; Zhu Y; Kumar R; Lin S
    Diabetes Metab Syndr Obes; 2021; 14():3417-3425. PubMed ID: 34349535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic dysfunction is associated with steatosis but no other histologic features in nonalcoholic fatty liver disease.
    Dai YN; Xu CF; Pan HY; Huang HJ; Chen MJ; Li YM; Yu CH
    World J Clin Cases; 2022 May; 10(13):4097-4109. PubMed ID: 35665109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibrosis-4 Index Score Predicts Concomitant Coronary Artery Diseases Across the Spectrum of Fatty Liver Disease.
    McNally BB; Rangan P; Wijarnpreecha K; Fallon MB
    Dig Dis Sci; 2023 Sep; 68(9):3765-3773. PubMed ID: 37392337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MAFLD might be better in identifying subjects with sarcopenia or cardiovascular risk than NAFLD: A nationwide study.
    Han E; Chun HS; Lee YH; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Lee BW; Kang ES; Cha BS; Ahn SH; Kim SU
    J Gastroenterol Hepatol; 2023 Sep; 38(9):1598-1609. PubMed ID: 37321651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discrepancies between Nonalcoholic and Metabolic-associated Fatty Liver Disease by Multiple Steatosis Assessment.
    Shao C; Ye J; Li X; Lin Y; Feng S; Liao B; Wang W; Gong X; Zhong B
    J Clin Transl Hepatol; 2022 Dec; 10(6):1013-1026. PubMed ID: 36381107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic dysfunction-associated fatty liver disease and nonalcoholic fatty liver disease from clinical to pathological characteristics: a multi-center cross-sectional study in real world.
    Li Y; Dai C; Ruan Y; Yang H; Zeng H; Huang R; Wang J; Dai M; Hao J; Wang L; Li J; Yan X; Lu Z; Ji F
    Postgrad Med J; 2024 Apr; 100(1183):319-326. PubMed ID: 38272486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of all-cause mortality associated with non-alcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease in Taiwan MJ cohort.
    Cheng WC; Chen HF; Cheng HC; Li CY
    Epidemiol Health; 2024; 46():e2024024. PubMed ID: 38317531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact on Prevalence of the Application of NAFLD/MAFLD Criteria in Overweight and Normal Weight Patients.
    Ordoñez-Vázquez AL; Juárez-Hernández E; Zuarth-Vázquez JM; Ramos-Ostos MH; Uribe M; Castro-Narro G; López-Méndez I
    Int J Environ Res Public Health; 2022 Sep; 19(19):. PubMed ID: 36231529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B.
    van Kleef LA; Choi HSJ; Brouwer WP; Hansen BE; Patel K; de Man RA; Janssen HLA; de Knegt RJ; Sonneveld MJ
    JHEP Rep; 2021 Oct; 3(5):100350. PubMed ID: 34557660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does the risk of cardiovascular events differ between biopsy-proven NAFLD and MAFLD?
    Guerreiro GTS; Longo L; Fonseca MA; de Souza VEG; Álvares-da-Silva MR
    Hepatol Int; 2021 Apr; 15(2):380-391. PubMed ID: 33694066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinic-pathological features of metabolic associated fatty liver disease with hepatitis B virus infection.
    Wang MF; Wan B; Wu YL; Huang JF; Zhu YY; Li YB
    World J Gastroenterol; 2021 Jan; 27(4):336-344. PubMed ID: 33584066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-invasive Screening of Metabolic Associated Fatty Liver Disease and Affecting Factors in Primary Care.
    Balci IC; Haciagaoglu N; Oner C; Cetin H; Simsek EE
    J Coll Physicians Surg Pak; 2023 Apr; 33(4):390-395. PubMed ID: 37190709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of HBV infection on clinical outcomes in patients with metabolic dysfunction-associated fatty liver disease.
    Cheng YM; Hsieh TH; Wang CC; Kao JH
    JHEP Rep; 2023 Sep; 5(9):100836. PubMed ID: 37600956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MAFLD identifies patients with significant hepatic fibrosis better than NAFLD.
    Yamamura S; Eslam M; Kawaguchi T; Tsutsumi T; Nakano D; Yoshinaga S; Takahashi H; Anzai K; George J; Torimura T
    Liver Int; 2020 Dec; 40(12):3018-3030. PubMed ID: 32997882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and Histologic Features of Patients with Biopsy-Proven Metabolic Dysfunction-Associated Fatty Liver Disease.
    Huang SC; Su HJ; Kao JH; Tseng TC; Yang HC; Su TH; Chen PJ; Liu CJ
    Gut Liver; 2021 May; 15(3):451-458. PubMed ID: 33431715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of nonalcoholic fatty liver disease (NAFLD) related steatosis indices in metabolic associated fatty liver disease (MAFLD) and comparison of the diagnostic accuracy between NAFLD and MAFLD.
    Chen J; Mao X; Deng M; Luo G
    Eur J Gastroenterol Hepatol; 2023 Apr; 35(4):394-401. PubMed ID: 36695773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of MAFLD and NAFLD Characteristics in Children.
    Xing Y; Fan J; Wang HJ; Wang H
    Children (Basel); 2023 Mar; 10(3):. PubMed ID: 36980118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Analysis of clinical characteristics and risk factors of hepatic fibrosis in children with chronic hepatitis B combined with metabolic-related fatty liver disease].
    Li W; Jiang LN; Zhao BK; Liu HY; Zhao JM
    Zhonghua Gan Zang Bing Za Zhi; 2023 Jun; 31(6):601-607. PubMed ID: 37400384
    [No Abstract]   [Full Text] [Related]  

  • 19. Impact and usefulness of the transition to the new MAFLD classification for non-B, non-C HCC: a retrospective cohort study.
    Johira Y; Nakahara T; Kinami T; Yamasaki S; Kosaka M; Shirane Y; Miura R; Murakami S; Yano S; Amioka K; Naruto K; Ando Y; Kosaka Y; Kodama K; Uchikawa S; Fujino H; Ono A; Murakami E; Okamoto W; Yamauchi M; Kawaoka T; Hayes CN; Tsuge M; Imamura M; Aikata H; Oka S
    BMC Gastroenterol; 2023 Jun; 23(1):222. PubMed ID: 37380950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of nomenclature as metabolic associated steatotic liver disease on steatotic liver disease prevalence and screening: a prospective population survey in Asians.
    Wu T; Ye J; Mo S; Ye M; Li X; Li Q; Wang W; Zheng Q; Luo K; Zhang Y; Tu S; Che D; Gong R; Chen X; Miu R; Shao C; Sun Y; Zhong B
    J Gastroenterol Hepatol; 2024 Aug; 39(8):1636-1647. PubMed ID: 38695344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.